PET tracer for imaging of neuroendocrine tumors
There is provided a radiolabelled peptide-based compound for diagnostic imaging using positron emission tomography (PET). The compound may thus be used for diagnosis of malignant diseases. The compound is particularly useful for imaging of somatostatin overexpression in tumors, wherein the compound is capable of being imaged by PET when administered with a target dose in the range of 150-350 MBq, such as 150-250 MBq, preferable in the range of 191-210 MBq.
1. A method for imaging a neuroendocrine tumor in a human patient, the method comprising:
a) administering to a human patient an imaging composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof:
b) conducting a radiographic imaging method on the patient after administration of the imaging composition; and
c) making a radiographic image of the patient for detecting the compound of Formula I;
wherein the radiographic image is diagnostic for the presence of a neuroendocrine tumor in the patient.
2. The method of claim 1 , wherein the imaging composition further comprises a scavenger.
3. The method of claim 2 , wherein the scavenger is gentisic acid.
4. The method of claim 1 , wherein the imaging composition further comprises sodium acetate.
5. The method of claim 1 , wherein the tumor is a neuroendocrine tumor metastasis.
6. The method of claim 1 , wherein the radiographic imaging method is performed 1 hour after administration of the imaging composition.
7. The method of claim 1 , wherein the radiographic imaging method is performed 3 hours after administration of the imaging composition.
8. The method of claim 1 , wherein the radiographic imaging method is performed 24 hours after administration of the imaging composition.
9. The method of claim 1 , wherein the radiographic imaging method is selected from the group consisting of planar imaging, positron emission tomography (PET), computed tomography (CT), single photon computed tomography (SPECT), and combinations thereof.